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ABSTRACT
The isolation and characterization of streptozotocin (STZ)-
induced mutations in the phage P22 mnt repressor gene is des-
cribed. Cells carrying the plasmid-borne mnt gene were exposed
to STZ to give 10-20 percent survival and at least an eleven-fold
increase in mutation frequency. DNA sequence analysis showed
that 50 of 51 STZ-induced mutations were GC to AT transitions,
and one was an AT to GC transition. We have also compared the
STZ mutational spectrum to that for N-methyl-N'-nitro-N-nitroso-
guanidine (MNNG). There are sites in the mnt gene which are
mutated only by STZ; only by MNNG, or by both agents. Sites at
which only STZ induced GC to AT transition mutations occur were
in sequences that are pyrimidine rich 5' to the mutated site and
purine rich 3' to the mutated site. Induction of mutations by
both STZ and MNNG should be considered to maximize the number of
mutable sites.
INTRODUCTION
Streptozotocin (STZ) is a monofunctional nitrosourea which
is a potent mutagen and carcinogen (1). It is used in the treat-
ment of patients with islet cell tumors and can also produce
insulitis in experimental animals (2). In an effort to determine
the underlying mechanisms of these drug effects, we have studied
the response of Escherichia coli cells to STZ exposure.
We have previously shown that E. coli ada and alkA mutants
are more sensitive to STZ, suggesting that the adaptive response
is an important factor in cell survival (3). The adaptive res-
ponse promotes transcription of certain genes which enhance
survival and decrease mutagenesis after exposure to alkylating
agents. The ada gene product acts as a positive regulator of
this regulon in addition to its role as an alkyl transferase.
After transfer of alkyl groups from phosphotriesters in DNA to
Ada protein, the methylated Ada protein increases transcription
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of ada, alkA, alkB and aidB genes. The alkA gene specifies 3-
methyladenine DNA glycosylase II, while the products of the
alkB and aidB genes are not yet known. As expected from the
above, STZ exposure induces transcription of ada, aidB alkA, and
aidD (but not aidC), suggesting that STZ causes formation of
methylphosphotriesters in DNA (4).
E. coli recA but not uvrA mutants are also more sensitive to
STZ than wild type (3). This indicates that the UvrABC endo-
nuclease is not required for repair of cytotoxic STZ lesions.
The requirement for RecA protein in cell survival could be its
function in either post-replication repair and/or its role in the
SOS response.
STZ is a potent mutagen. Our prior studies showed that pre-
mutagenic lesions were repaired by 06-alkylguanine-DNA alkyl
transferase since an ada mutant strain was hypermutable compared
to the same strain that contained a wild type ada gene on a
plasmid (3). Furthermore, an inverse correlation was observed
between the amount of Ada protein in the cell and the level of
mutagenesis. This mechanism of Ada-dependent mutagenesis is
common among methylating agents, such as N-methyl-N'-nitroso-N-
nitrosoguanidine (MNNG), which produce 06_methylguanine (06_MeG)
alkylation (5).
We have previously determined the mutagenic specificity of
MNNG using a forward mutation system (6). We characterized and
sequenced mutations induced in the phage P22 mnt repressor gene
present in cells on a multicopy pBR322 derived plasmid. We now
have used the same DNA target to define mutational sites induced
by STZ, and compared the specificity of the two mutagens. Al-
though both agents are Ada-dependent mutagens the location of the
mutations induced by each is significantly different.
MATERIALS AND METHODS
Bacterial strains and plasmids
Strain GM3136 is AB1157 (7) containing F-42 and plasmid
pPY97. Plasmid pPY97 is identical to pPY98 (6) except that the
M13 origin of replication is inverted. Strain MM294 (8) was
obtained from the Coli Genetic Stock Center, Department of
Biology, Yale University, Box 6666, New Haven, CT 06520, USA.
9812
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Isolation of tetracycline-resistant strains
Strain GM3136 was grown at 37 C in Brain Heart Infusion
broth (BHA broth; Difco; 20 g per liter) containing 40 ug ampici-
llin per ml to approximately 1 x 108 cells per ml. The culture
was centrifuged and resuspended in minimal salts medium (9)
without glucose. STZ (Sigma Chemical Corp.) was added to 100 uM
final concentration and after 30 min incubation at 37 C, the
cells were harvested, washed and 10 ul portions diluted into
several 1 ml BHA broths and incubated overnight at 37 C. Next
day, 0.1 ml from each broth culture was inoculated onto BHA agar
containing 3.5 ug tetracycline per ml and incubated overnight at
37 C. A single mutant colony from each plate was purified three
times on media containing 10 ug tetracycline per ml.
Identification of mnt mutants
Each tetracycline-resistant colony was tested genetically as
described (6), to identify those containing mutations in the mnt
region.
DNA sequencing analysis
Plasmid DNA from tetracycline-resistant mnt derivatives of
strain GM3136 was isolated (10) and used to transform strain
MM294 to tetracycline-resistance. This step ensured that plasmid
DNA for sequencing was derived from a single molecule, and in
addition, DNA isolated from an endA mutant strain (MM294) gave
more consistent DNA sequencing results. Isolation of plasmid DNA
was as described (11,12) and sequenced according to the enzymatic
method of Sanger et al (13) as previously described (8).
RESULTS
Experimental system
The experimental system to identify mutations has been des-
cribed in detail (6,8) and therefore only a summary is given
here. We use the 252 base-pair mnt gene as a target to monitor
mutations. This gene is present on a pBR322 derivative (pPY97)
as an operon fusion (Figure 1). Mnt repressor binds to its
operator preventing transcription from the ant promoter and thus
cells which are Mnt+ are tetracycline sensitive. Mutations in
mnt or its operator prevent repressor binding and permit tran-
scription of the tetA gene from the ant promoter, resulting in a
9813
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Figure 1. Genetic map of the mnt-tetA fusion region. The heavy
lines indicate pBR322 DNA and E and H denote the EcoRI and
HindIII recognition sites respectively. The thin line indicates
phage P22 DNA and shows the mnt gene and its operator (0 t) ,and
the promoters for the ant and mnt genes. Mutation in mnt'
promotes transcription from the ant promoter through the tetA
gene to yield a tetracycline-resistant phenotype.
tetracycline-resistant phenotype. A simple genetic test can
distinguish mutations in mnt from those in the operator region
(6). Plasmid DNA from mnt mutant strains is isolated by a rapid
mini-prep method (11,12) and subjected to enzymatic DNA sequen-
cing (13).
Mutation induction
Cells were exposed to 100 uM STZ for 30 min which resulted
in 10-20 percent survival. The mutation frequency increased by
Table 1. Location of mutations in the mnt gene arising after
induction with STZ.
Number Position Codon change
-33
+12
+40
+41
+52
+53
+110
+130
+139
+152
G to A
G
CAC
CAC
CGT
CGT
TCA
CAA
CAA
to A
to TAC
to CGC
to TGT
to CAT
to TTA
to TAA
to TAA
TCA to TTA
Amino Acid Change
Promoter
Ribosome binding
His6 to Tyr
His6 to Arg
ArglO to Cys
ArglO to His
Ser29 to Leu
Gln36 to Stop
Gln39 to Stop
Ser43 to Leu
Bases are numbered with respect to the starting point of tran-
scription (+1) of the mnt gene. The translation initiation
codon is at position 21-23.
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Figure 2. Sites in the mnt gene mutated by STZ and MNNG. The
number and position of identified mutations induced by STZ and
MNNG are shown above and below the base line respectively.
at least 11-fold from a basal level of approximately 1 tetra-
cycline-resistant mutant per 108 cells plated.
STZ-induced mutations
Table 1 shows the results from sequencing 51 independent
STZ-induced mutations. All are transition mutations: 50 are GC
to AT base pair changes, and one is an AT to GC base pair change.
Of these mutations, 13 are in the promoter, 2 in the region
corresponding to the 5'-untranslated leader mRNA, and the rest in
the coding sequence of the mnt gene. Mutations in the coding
region are restricted to the first 152 bases of the 252 base pair
gene. This region of the mnt gene codes for the amino terminal
end of the repressor which is required for DNA binding.
Table 1 also shows that nine GC base pairs at various sites
in the DNA were mutated by STZ. Of these, six G residues are in
the non-transcribed strand, and three on the transcribed strand,
suggesting a strand preference for mutability. On the other
hand, the total number of mutations occurring on the transcribed
and non-transcribed strands, was 21 and 29, respectively.
Two sites (-33 and +130) are major "hotspots" for mutation.
One of these is in the -35 region of the mnt promoter, and
decreases promoter strength. The change at site 130 results in
the generation of a translational stop codon. Together the
mutations at the hotspots comprise 24/51, or about half of all
the mutations (Fig. 2).
Sequence specificity
Fig. 2 and Table 2 show the sites in the mnt gene mutated by
9815
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Table 2. Effect of surrounding nucleotide sequence on mutational
specificity of MNNG and STZ.
Sites mutable by Sites mutable by Sites mutable by
MNNG only MNNG and STZ STZ only
+24 CATG G GCTA +40 AAGT G CGGA -33 TATT G AGAA
+91 CAGG G CGGA +52 ATAC G GAAG +12 CTTG G AGTG
+121 CTCC G AGTT +53 TTCC G TATG +139 TCTT G GACG
+110 CATT G ATCT +152 TTTT G ATAG
+130 ATTT G TACC
The numbers refer to sites where G to A mutations have occured
and these are indicated by the middle G in each sequence. For
each sequence the four upstream and the four downstream nucleo-
tides surrounding the mutated G are included.
STZ and MNNG. These sites can be divided into three types:
those mutable by STZ only; or by MNNG only; or by both agents
(Table 2). To examine the effect of flanking DNA sequence on
mutation specificity, the number of purines and pyrimidines four
bases before and after the mutated guanine residue has been
determined. For the MNNG only class, at sites 24, 91 and 121,
there are a total of 5 purines and 7 pyrimidines 5' to the
mutated G and 7 purines and 5 pyrimidines on the 3' side. For
sites mutated by both agents, there are 7 purines and 13 pyrimi-
dines 5' to the mutated G and 12 purines and 8 pyrimidines 3'.
That is, the frequency of purines and pyrimidines is about the
same upstream or downstream of the mutational site. For the STZ
only class, however, there is a striking difference in purine and
pyrimidine frequency compared to the other two classes. There
are two purines and 14 pyrimidines upstream of the mutated G, and
13 purines and 3 pyrimidines downstream. Therefore, sequences
containing a central GC base pair with a 5' pyrimidine-rich
region and a 3' purine-rich region are particularly prone to
mutation by STZ.
DISCUSSION
STZ produces predominantly GC to AT base pair changes. This
observation is in accord with the hypothesis that 06-MeG is respo-
9816
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nsible for the high mutagenicity of STZ. 06-MeG pairing with
thymine (14) produces GC to AT transition mutations (6,15,16).
Our previous data (4), showing that ada mutants are hypermutable
by STZ and that overproduction of Ada protein reduces mutagene-
sis, are in agreement with this hypothesis. 06-MeG has been
detected in DNA after exposure of cells to STZ (17).
One of the mutations induced in the mnt gene was an AT to GC
transition. Although we cannot exclude the possibility that this
mutation arose spontaneously, it is more probable that it
resulted from the formation of 04-methylthymine. This modified
base can pair with guanine to produce AT to GC transitions.
Alternatively, the presence of N3-methyladenine could provoke an
SOS-dependent mutational event.
The results with STZ contrast sharply to the spontaneous
mutation spectrum in the same bacterial strain. Spontaneous
mutations are mostly IS1 insertions and a minor class are dele-
tions in the operator region (8,18). Single base changes have
never been detected. This indicates that the base changes in mnt
isolated from STZ-exposed cells are the direct result of drug
exposure and not due to spontaneous mutation.
MNNG-induced mutations in the mnt gene did not show any
strand specificity (6). STZ mutable sites, however, are twice as
frequent on the nontranscribed strand (Table 2), although it
should be noted that the sample size is small. In studies with
MNNG by others, a strand preference could be demonstrated for the
cI gene of phage lambda (19) and the gpt gene of E. coli (20) but
not for lacI (21). Burns et al (21) reported that the most
mutable sites induced with MNNG in lacI were those with a 5'
flanking purine. In contrast, the most mutable sites in mnt
after MNNG or STZ exposure are those with a 5' flanking pyrimi-
dine (Table 2).
STZ-induced mutational sites could be classified into two
classes. In one class are those mutations specific for STZ,
while the other class consists of sites mutable by both STZ and
MNNG. The latter are in DNA sequences that do not appear to
differ from MNNG mutable sites whereas the former show a distinct
pattern of a pyrimidine-rich stretch of bases followed by a set
of purines. The four sites mutated by STZ only are not the only
9817
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ones in mnt showing this feature. The sequences surrounding the
guanines at positions +63, +89, and +120 are CTAT G GAAG, TTCA G
GGCG, and ACTC G GAGT, respectively. Mutation of the G at +120
to an A would conserve the serine codon and would thus be silent.
Changes at +63 and +89, however, should result in replacement of
methionine to isoleucine, and arginine to lysine, respectively.
Whether these positions are not mutated by STZ or if they are
mutated but that the amino acid replacements are permissable is
not yet known. The latter alternative is distinctly possible
since G to A mutations at positions +63 and +89 have never been
isolated in our studies with this gene.
It should be stressed that the sample size in the above
analysis is small, a problem common to all such studies of this
type. What was striking, however, is that within such a small
sample both STZ and MNNG each showed site preferences for
mutation despite their action through a common mechanism. We
suggest that the use of STZ as an adjunct to MNNG is advantageous
in order to broaden the mutation spectrum.
The causes underlying differences in mutational specificity
of STZ and MNNG are unclear. Among the possibilities are that
differences exist in the sites of methylation by each drug and/or
in subsequent processing of lesions. For example, MNNG produces
base mismatches subject to Dam-dependent mismatch repair (22) but
STZ does not (3). This may indicate that MNNG produces certain
types of modification that are not formed by STZ. Another diffe-
rence is that MNNG induces transcription of the aidC gene while
STZ does not (4). While the function of aidC is not known, it is
apparent that expression of other genes involved in DNA repair
might also be induced by one drug and not the other, thus causing
differences in the mutation spectrum.
There are two differences between the experimental systems
used for the MNNG and STZ studies. First, the plasmid used in
the STZ study is identical to that for the MNNG spectrum (6)
except that its M13 origin of replication is inverted. Since it
has been shown that the M13 origin has no effect on mutation
spectrum in mnt (8,18), this possibility seems unlikely to explain
differences in spectrum. Second, a recF143 strain was used for
the MNNG study while a wild type strain was used for the STZ
9818
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spectrum. Although the recF gene product has been implicated
in ultra-violet light mutagenesis (5), we know of no published
evidence for its involvement in Ada-dependent mutagenesis. As
previously reported (6), we could not detect a difference in
MNNG-induced mutation frequency in mnt between recF143 and wild
type strains. Therefore, although we cannot exclude the
possibility that recF affects the spectrum of alkylation-induced
mutagenesis, we believe it is unlikely.
Lastly, although structurally distinct from MNNG, STZ is
also an N-nitroso compound that methylates DNA. While the sites
of alkylation do not differ among a wide spectrum of methylating
agents, the extent of methylation at specific sites may vary
(23). Thus, differences in the extent to which specific lesions
are formed, whether as a result of varying intracellular drug
concentrations or chemical reactivity, may also explain our re-
sults. These issues are currently being addressed.
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